SG11201403311SA - Non-sialylated anti-inflammatory polypeptides - Google Patents

Non-sialylated anti-inflammatory polypeptides

Info

Publication number: SG11201403311SA
Authority: SG; Singapore
Prior art keywords: inflammatory polypeptides; sialylated anti; sialylated; polypeptides; inflammatory
Prior art date: 2011-12-19

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-10Application filed by Univ RockefellerfiledCriticalUniv Rockefeller

2014-07-30Publication of SG11201403311SApublicationCriticalpatent/SG11201403311SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)

SG11201403311SA2011-12-192012-12-10Non-sialylated anti-inflammatory polypeptidesSG11201403311SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161577361P	2011-12-19	2011-12-19
PCT/US2012/068718WO2013095966A1 (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides

Publications (1)

Publication Number	Publication Date
SG11201403311SAtrue SG11201403311SA (en)	2014-07-30

Family

ID=48669359

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG11201403311SASG11201403311SA (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides
SG10202001596VASG10202001596VA (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides
SG10201805962PASG10201805962PA (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG10202001596VASG10202001596VA (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides
SG10201805962PASG10201805962PA (en)	2011-12-19	2012-12-10	Non-sialylated anti-inflammatory polypeptides

Country Status (15)

Country	Link
US (5)	US9587025B2 (en)
EP (2)	EP3485909A1 (en)
JP (6)	JP6322872B2 (en)
CN (2)	CN104010659A (en)
AU (1)	AU2012355710B2 (en)
CA (1)	CA2859022A1 (en)
EA (2)	EA201892339A3 (en)
ES (1)	ES2692539T3 (en)
IL (2)	IL233082B (en)
IN (1)	IN2014CN04765A (en)
MX (1)	MX357923B (en)
PT (1)	PT2793943T (en)
SG (3)	SG11201403311SA (en)
WO (1)	WO2013095966A1 (en)
ZA (1)	ZA201405185B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
SG11201403311SA (en)	2011-12-19	2014-07-30	Univ Rockefeller	Non-sialylated anti-inflammatory polypeptides
US12384848B2 (en)	2011-12-19	2025-08-12	The Rockefeller University	Anti-inflammatory polypeptides
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015054039A1 (en)*	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Fc CONTAINING POLYPEPTIDES HAVING INCREASED BINDING TO FcGammaRIIB
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
CN107250157B (en)	2014-11-21	2021-06-29	百时美施贵宝公司	Antibodies comprising modified heavy chain constant regions
CA2968357A1 (en)	2014-11-21	2016-05-26	Bristol-Myers Squibb Company	Antibodies against cd73 and uses thereof
KR102644115B1 (en)	2014-12-23	2024-03-05	브리스톨-마이어스 스큅 컴퍼니	Antibodies to tigit
CA2978580A1 (en)*	2015-03-04	2016-09-09	The Rockefeller University	Anti-inflammatory polypeptides
WO2016154118A1 (en)	2015-03-20	2016-09-29	The Rockefeller University	Immune complex
TN2019000101A1 (en)	2015-05-29	2020-07-15	Bristol Myers Squibb Co	Antibodies against ox40 and uses thereof.
EP3313886A1 (en)	2015-06-29	2018-05-02	The Rockefeller University	Antibodies to cd40 with enhanced agonist activity
FR3038517B1 (en)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
EP4406550A3 (en)	2016-03-04	2024-10-16	The Rockefeller University	Antibodies to cd40 with enhanced agonist activity
IL295230A (en)	2016-03-04	2022-10-01	Bristol Myers Squibb Co	Combination therapy with anti-cd73 antibodies
WO2018106885A1 (en)	2016-12-07	2018-06-14	East Carolina University	Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
TWI788340B (en)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	Anti-icos agonist antibodies and uses thereof
EP4098662A1 (en)	2017-05-25	2022-12-07	Bristol-Myers Squibb Company	Antibodies comprising modified heavy constant regions
CN111032688A (en)*	2017-08-11	2020-04-17	研究发展基金会	Engineered antibody FC variants for extended serum half-life
WO2019125846A1 (en)	2017-12-19	2019-06-27	The Rockefeller University	HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
CN111788227B (en)	2017-12-27	2025-02-25	百时美施贵宝公司	Anti-CD40 antibodies and uses thereof
US20230053449A1 (en)	2018-10-31	2023-02-23	Novartis Ag	Dc-sign antibody drug conjugates
MY205758A (en)	2018-11-16	2024-11-12	Bristol Myers Squibb Co	Anti-nkg2a antibodies and uses thereof
JP2022513653A (en)	2018-11-28	2022-02-09	ブリストル－マイヤーズスクイブカンパニー	Antibodies containing modified heavy chain constant regions
US20230192867A1 (en)	2020-05-15	2023-06-22	Bristol-Myers Squibb Company	Antibodies to garp

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US20040002587A1 (en)*	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
US8188231B2 (en)	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US20040110930A1 (en)	2002-10-03	2004-06-10	Reinl Stephen J.	Multimeric protein engineering
EP1858925A2 (en)*	2005-01-12	2007-11-28	Xencor, Inc.	Antibodies and fc fusion proteins with altered immunogenicity
RU2007145509A (en)	2005-05-09	2009-06-20	Гликарт Биотехнологи Аг (Ch)	ANTIGEN BINDING MOLECULES HAVING MODIFIED FC SITES AND VARIABLE BINDING WITH FC RECEPTORS
EP1896071B1 (en)	2005-06-30	2015-04-29	Janssen Biotech, Inc.	Methods and compositions with enhanced therapeutic activity
US8470318B2 (en)	2005-11-07	2013-06-25	The Rockefeller University	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en)	2006-04-05	2008-08-28	Ravetch Jeffrey V	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2006312148B2 (en)	2005-11-07	2012-04-12	The Rockefeller University	Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
NZ572379A (en)	2006-04-05	2012-06-29	Univ Rockefeller	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ597651A (en)	2006-10-26	2012-07-27	Univ Rockefeller	Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2121756A4 (en)*	2006-12-20	2011-08-31	Mmrglobal Inc	Antibodies and methods for making and using them
WO2008083150A2 (en)*	2006-12-28	2008-07-10	Centocor Ortho Biotech Inc.	Methods and vectors for generating asialylated immunoglobulins
US20110020269A1 (en)	2007-05-08	2011-01-27	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for modifying t cell immune responses and inflammation
EP3176264B1 (en)*	2007-05-30	2018-09-26	Postech Academy-Industry- Foundation	Immunoglobulin fusion proteins
EP2242505A4 (en)*	2008-01-08	2012-03-07	Biogenerix Ag	Glycoconjugation of polypeptides using oligosaccharyltransferases
CA2722173A1 (en)	2008-04-22	2009-10-29	The Rockefeller University	Methods of identifying anti-inflammatory compounds
ES2622102T3 (en)*	2009-10-29	2017-07-05	Janssen Biotech, Inc.	Glycosylation antibody variants
KR20240025059A (en)*	2010-11-30	2024-02-26	추가이 세이야쿠 가부시키가이샤	Cytotoxicity-inducing therapeutic agent
EP2656073A4 (en)*	2010-12-20	2014-12-17	Univ Rockefeller	MODULATION OF ANTI-TNFR AGONIST ANTIBODIES
JP2014513678A (en)*	2011-04-07	2014-06-05	ネオトープバイオサイエンシーズリミテッド	Compositions and methods for treating diseases related to protein aggregation with IC3B deposition
US20130273089A1 (en)*	2011-11-03	2013-10-17	Tolera Therapeutics, Inc.	Antibody and methods for selective inhibition of t-cell responses
SG11201403311SA (en)	2011-12-19	2014-07-30	Univ Rockefeller	Non-sialylated anti-inflammatory polypeptides

2012
- 2012-12-10SGSG11201403311SApatent/SG11201403311SA/enunknown
- 2012-12-10CNCN201280062837.8Apatent/CN104010659A/enactivePending
- 2012-12-10MXMX2014007292Apatent/MX357923B/enactiveIP Right Grant
- 2012-12-10EPEP18196115.2Apatent/EP3485909A1/enactivePending
- 2012-12-10CACA2859022Apatent/CA2859022A1/enactivePending
- 2012-12-10ESES12860516.9Tpatent/ES2692539T3/enactiveActive
- 2012-12-10USUS14/368,701patent/US9587025B2/enactiveActive
- 2012-12-10AUAU2012355710Apatent/AU2012355710B2/enactiveActive
- 2012-12-10ININ4765CHN2014patent/IN2014CN04765A/enunknown
- 2012-12-10EPEP12860516.9Apatent/EP2793943B1/enactiveActive
- 2012-12-10EAEA201892339Apatent/EA201892339A3/enunknown
- 2012-12-10PTPT12860516Tpatent/PT2793943T/enunknown
- 2012-12-10JPJP2014549097Apatent/JP6322872B2/enactiveActive
- 2012-12-10SGSG10202001596VApatent/SG10202001596VA/enunknown
- 2012-12-10EAEA201491215Apatent/EA031715B1/enunknown
- 2012-12-10WOPCT/US2012/068718patent/WO2013095966A1/enactiveApplication Filing
- 2012-12-10CNCN202311583469.8Apatent/CN117964709A/enactivePending
- 2012-12-10SGSG10201805962PApatent/SG10201805962PA/enunknown
2014
- 2014-06-12ILIL233082Apatent/IL233082B/enactiveIP Right Grant
- 2014-07-15ZAZA2014/05185Apatent/ZA201405185B/enunknown
2015
- 2015-03-04USUS14/638,905patent/US9845358B2/enactiveActive
2017
- 2017-12-18USUS15/845,487patent/US10894832B2/enactiveActive
- 2017-12-27JPJP2017251227Apatent/JP2018093874A/enactivePending
2019
- 2019-08-19ILIL268787Apatent/IL268787B/enunknown
- 2019-11-22JPJP2019211501Apatent/JP7044267B2/enactiveActive
2020
- 2020-11-20USUS16/953,639patent/US11608379B2/enactiveActive
- 2020-11-25USUS17/104,125patent/US11613579B2/enactiveActive
2021
- 2021-01-07JPJP2021001368Apatent/JP2021063117A/enactivePending
2022
- 2022-03-04JPJP2022033240Apatent/JP2022091768A/enactivePending
2024
- 2024-06-26JPJP2024102976Apatent/JP2024125369A/enactivePending

Also Published As

Publication number	Publication date
US9587025B2 (en)	2017-03-07
ZA201405185B (en)	2015-06-24
JP2024125369A (en)	2024-09-18
US9845358B2 (en)	2017-12-19
EP2793943A4 (en)	2015-03-04
US20210130472A1 (en)	2021-05-06
PT2793943T (en)	2018-11-13
US11613579B2 (en)	2023-03-28
US20160319024A9 (en)	2016-11-03
EP2793943B1 (en)	2018-09-26
US10894832B2 (en)	2021-01-19
NZ627002A (en)	2016-08-26
MX357923B (en)	2018-07-30
IL268787A (en)	2019-10-31
JP2021063117A (en)	2021-04-22
US20150376280A1 (en)	2015-12-31
EA201491215A1 (en)	2015-02-27
IL233082A0 (en)	2014-07-31
IN2014CN04765A (en)	2015-09-18
JP2015504883A (en)	2015-02-16
JP7044267B2 (en)	2022-03-30
WO2013095966A1 (en)	2013-06-27
ES2692539T3 (en)	2018-12-04
JP6322872B2 (en)	2018-05-16
SG10201805962PA (en)	2018-08-30
JP2018093874A (en)	2018-06-21
CN117964709A (en)	2024-05-03
CA2859022A1 (en)	2013-06-27
US20210101986A1 (en)	2021-04-08
JP2020039357A (en)	2020-03-19
EA201892339A2 (en)	2019-03-29
AU2012355710A1 (en)	2014-08-07
AU2012355710B2 (en)	2017-11-02
BR112014014549A2 (en)	2020-09-24
US20140377280A1 (en)	2014-12-25
EP3485909A1 (en)	2019-05-22
EA201892339A3 (en)	2019-06-28
US20180179284A1 (en)	2018-06-28
EP2793943A1 (en)	2014-10-29
HK1203374A1 (en)	2015-10-30
IL268787B (en)	2021-09-30
MX2014007292A (en)	2014-09-08
SG10202001596VA (en)	2020-04-29
US11608379B2 (en)	2023-03-21
EA031715B1 (en)	2019-02-28
IL233082B (en)	2019-09-26
JP2022091768A (en)	2022-06-21
CN104010659A (en)	2014-08-27

Publication	Publication Date	Title
IL268787B (en)	2021-09-30	Sialylated anti-inflammatory polypeptides
IL291571A (en)	2022-05-01	Cx3cr1-binding polypeptides
ZA201309174B (en)	2022-08-31	Polypeptides
PL2535471T3 (en)	2017-07-31	Shelter
EP2768696A4 (en)	2015-04-15	Seat-track assembly
GB201104597D0 (en)	2011-05-04	Building
GB2503394B (en)	2016-04-20	Connection assembly
GB201220474D0 (en)	2012-12-26	Polypeptides
PL2771471T3 (en)	2017-10-31	Construct
PL2663704T3 (en)	2016-03-31	Bivouac shelter
GB201401148D0 (en)	2014-03-12	Connection fixture
EP2751136A4 (en)	2015-07-08	Natriuretic polypeptides
ZA201404753B (en)	2015-09-30	Panels
GB2492472B (en)	2015-12-16	Connection mechanism
SI2492413T1 (en)	2013-03-29	Awning
PT2938353T (en)	2018-11-20	Anti-inflammatory peptides
GB2512771B (en)	2018-02-21	Ablutionary fitting
PL2599930T3 (en)	2016-08-31	Tile assembly
GB201111134D0 (en)	2011-08-17	Building
IL232370A0 (en)	2014-06-30	Tampon-applicator assembly
GB201118564D0 (en)	2011-12-07	Lopck assembly
PL2474682T3 (en)	2019-01-31	Awning
PT2718316T (en)	2020-05-04	Polypeptides
GB201100686D0 (en)	2011-03-02	Building improvements
HU4101U (en)	2012-03-28	Light-structure building

Movatterモバイル変換

SG11201403311SA - Non-sialylated anti-inflammatory polypeptides - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=48669359

Family Applications (3)

Family Applications After (2)

Country Status (15)

Families Citing this family (35)

Family Cites Families (24)

Also Published As

Similar Documents